China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Scheduled to Reverse Split on Monday, October 26th

by · The Markets Daily

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report) are going to reverse split on the morning of Monday, October 26th. The 1-100 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 25th.

China SXT Pharmaceuticals Stock Performance

Shares of NASDAQ:SXTC traded down $0.03 on Thursday, reaching $0.05. The company’s stock had a trading volume of 55,565,881 shares, compared to its average volume of 60,694,356. The stock’s 50-day moving average is $2.22 and its two-hundred day moving average is $89.02. China SXT Pharmaceuticals has a 52-week low of $0.05 and a 52-week high of $83,758.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SXTC. Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, China SXT Pharmaceuticals has an average rating of “Sell”.

Check Out Our Latest Research Report on China SXT Pharmaceuticals

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.

Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.

China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.

Featured Articles